胰高血糖素样肽-1受体激动剂与胃肠道不良事件:系统综述与Meta分析
本系统综述与Meta分析纳入55项安慰剂对照随机对照试验共106,395例参与者,评估GLP-1RAs与胃肠道及胆道不良事件的风险。结果显示GLP-1RAs增加胆石症风险(RR 1.46;95%CI 1.09-1.97)并可能增加胃食管反流病风险(RR 2.19;95%CI 1.48-3.25),对其他胃肠道或胆道事件风险似乎影响很小或没有影响。
要点
- GLP-1RAs增加胆石症风险(RR 1.46;95%CI 1.09-1.97),每1000例多2例。
- GLP-1RAs可能增加胃食管反流病风险(RR 2.19;95%CI 1.48-3.25),每1000例多4例。
- GLP-1RAs对其他胃肠道或胆道事件风险似乎影响很小或没有影响。
核心结论
- GLP-1RAs与胆石症和胃食管反流病风险增加相关,但似乎不增加其他胃肠道或胆道不良事件的风险。
研究设计与样本
- 系统检索5个数据库的安慰剂对照随机对照试验,纳入报告特定胃肠道或胆道不良事件的试验,共55项随机对照试验、106,395例参与者。
- 采用随机效应模型进行Meta分析,并按患者人群、GLP-1RA与双激动剂制剂、减重特征、剂量和作用持续时间进行亚组分析。
主要发现
- 与安慰剂相比,GLP-1RAs增加胆石症风险(RR 1.46;95%CI 1.09-1.97;每1000例多2例)。
- 与安慰剂相比,GLP-1RAs可能增加胃食管反流病风险(RR 2.19;95%CI 1.48-3.25;每1000例多4例)。
- GLP-1RAs对其他胃肠道或胆道事件风险似乎影响很小或没有影响。
- 亚组分析显示,在超重/肥胖或代谢功能障碍相关脂肪性肝炎/代谢功能障碍相关脂肪性肝病人群、减重性GLP-1RAs或高剂量制剂的试验中,胆石症和胃食管反流病风险增加更明显,但这些亚组效应未达统计学显著。
关键数值与推荐
- 胆石症:GLP-1RAs vs 安慰剂,RR 1.46(95%CI 1.09-1.97),每1000例多2例。
- 胃食管反流病:GLP-1RAs vs 安慰剂,RR 2.19(95%CI 1.48-3.25),每1000例多4例。
- 其他胃肠道或胆道事件:GLP-1RAs似乎影响很小或没有影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for glycemic control or weight management in patients with type 2 diabetes mellitus or overweight/obesity. However, there are concerns regarding their association with serious gastrointestinal adverse events, although findings have been inconsistent. METHODS: We systematically searched 5 databases for placebo-controlled randomized controlled trials assessing GLP-1RAs in patients with type 2 diabetes mellitus, overweight/obesity, or metabolic dysfunction-associated steatohepatitis/metabolic dysfunction-associated steatotic liver disease. We included trials that reported cholecystitis, cholelithiasis, cholangitis, cholestasis, pancreatitis, gastroesophageal reflux disease (GERD), gastritis, esophagitis, gastrointestinal ischemia, gastrointestinal hemorrhage, intestinal obstruction, paralytic ileus, gastrointestinal ulceration, gastrointestinal perforation, or gastroparesis. Meta-analyses were performed using a random-effects model, with subgroup analyses evaluating risks based on patient population, GLP-1RA vs dual-agonist formulation, weight-loss profile, dosing, and duration of action. RESULTS: We included 55 randomized controlled trials involving 106,395 participants. GLP-1RAs increased the risk of cholelithiasis (risk ratio [RR], 1.46; 95% CI, 1.09-1.97; 2 more cases per 1000) and probably increased the risk of GERD (RR, 2.19; 95% CI, 1.48-3.25; 4 more cases per 1000) compared with placebo. GLP-1RAs probably have little or no effect on the risk of other gastrointestinal or biliary events. Subgroup analyses showed that the increased risks of cholelithiasis and GERD were more pronounced in trials including individuals with overweight/obesity or metabolic dysfunction-associated steatohepatitis/metabolic dysfunction-associated steatotic liver disease, weight-loss-inducing GLP-1RAs, or high-dose formulations, although these subgroup effects were not statistically significant. CONCLUSIONS: GLP-1RAs are associated with an increased risk of cholelithiasis and GERD, but do not appear to increase the risk of other gastrointestinal or biliary adverse events.
引用
- Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025. PMID: 40499738. doi:10.1053/j.gastro.2025.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。